Program
LM-350
A development code. Also written as “LM-350 for injection”.
In Sino Biopharmaceutical's pipeline, CDH17 ADC
. Its studies are mostly in Neoplasms, led by Sino Biopharmaceutical.
Furthest: phase 2, since Jul 16, 20251 company-led study, 1 open or runningNext primary completion: Jun 30, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 11 open or running | phase 2since Jul 16, 2025 | Jul 16, 2025 | Jun 30, 2028phase 2 · NCT07112222 |
- Named in Sino Biopharmaceutical’s own pipeline as
LM-350
, phase 1, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 16, 2025First study: phase 2 study in NeoplasmsFirst studyNCT07112222 · 80 planned · Australia, China
Ahead
- Jun 30, 2028Primary completion: phase 2 study in NeoplasmsNCT07112222
TargetBeta
“CDH17 ADC”the company's pipeline, read by Claude · source
Other programs on CDH17
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-CDH17 Antibody-drug Conjugate HS-20110 | Hansoh Pharmaceutical Group | phase 2 | 2 |
| Anti-CDH17/MF-6 Antibody-drug Conjugate 7MW4911rule | Mabwell (Shanghai) Bioscience | phase 2 | 2 |
| AMT-676rule | multitude-therapeutics-inc | phase 2 | 2 |
| Anti-CDH17/Topoisomerase I Inhibitor Antibody-drug Conjugate DB-1324rule | dualitybio-inc | phase 2 | 1 |
| Anti-CDH17 Antibody-drug Conjugate YL217rule | MediLink Therapeutics (Suzhou) | phase 1 | 1 |
| Anti-CDH17/Exatecan Antibody-drug Conjugate ARR-217rule | arrivent-biopharma-inc | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07112222Neoplasms · Australia, China | 2 | Recruiting | Jun 30, 2028 | 80 |
How it is read
Names in the registry
- “LM-350 for injection”, 1 entry
Codes read as this program: LM350.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.